2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2962

MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Abstract Number: 1008

mtDNA Cybrids from OA Patients Are Less Efficient Using Glycolysis and Are More Susceptible to Apoptosis Under Stress Conditions
Abstract Number: 1746

mTOR Pathway Activation in Takayasu Arteriti
Abstract Number: 2932

mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Abstract Number: 2763

mTORC1 Blockade with Rapamycin and N-Acetylcysteine Reduces Anti-Phospholipid Antibody Levels in Controlled Clinical Trials of Patients with SLE
Abstract Number: 1065

Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus Is Realted to an Intrinsic Defect in the Ca2+/Calcineurin/NFAT1 Signaling Pathway
Abstract Number: 2711

Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Abstract Number: 759

Multi Dimensional Analysis of the Immunome in Systemic Sclerosis Reveals Functionally Related Abnormalities in MAIT and B Cell Compartments
Abstract Number: 414

Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Abstract Number: 361

Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
Abstract Number: 2931

Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems
Abstract Number: 1180

Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis
Abstract Number: 354

Multidomain Functional Assessment in a Cohort of Patients with Systemic Lupus Erythematosus: A Pilot Study
Abstract Number: 1959

Multimorbidity in Patients with Sarcoidosis: A Population-Based Cohort Study
Abstract Number: 2144

Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].